Sunita Mulpuru1,2,3, Melissa K Andrew4,5, Lingyun Ye5, Todd Hatchette6,7,5, Jason LeBlanc7,5, May El-Sherif5, Donna MacKinnon-Cameron5, Shawn D Aaron1,2,3, Gonzalo G Alvarez1,2,3, Alan J Forster1,2,3, Ardith Ambrose5, Shelly A McNeil6,5. 1. Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. 4. Department of Medicine (Geriatrics), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 5. Canadian Center for Vaccinology (CCfV), IWK Health Center, Nova Scotia Health, Halifax, Nova Scotia, Canada. 6. Department of Medicine (Infectious Diseases), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. 7. Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
BACKGROUND: Seasonal respiratory viral infections are associated with exacerbations and morbidity among patients with COPD. The real-world clinical outcomes associated with seasonal viral infections are less well established among hospitalized patients. RESEARCH QUESTION: To estimate the association between seasonal respiratory viral infections, 30-day mortality, and intensive care unit (ICU) admission among hospitalized COPD patients. STUDY DESIGN AND METHODS: We conducted an analysis of a national prospective multicenter cohort of COPD patients hospitalized with acute respiratory illness during winter seasons (2011-2015) in Canada. Nasopharyngeal swabs were performed on all patients at the onset of hospital admission for diagnosis of viral infection. Primary outcomes were 30-day mortality and ICU admissions. Secondary outcomes included invasive/non-invasive ventilation use. RESULTS: Among 3931 hospitalized patients with COPD, 28.5% (1122/3931) were diagnosed with seasonal respiratory viral infection. Viral infection was associated with increased admission to ICU (OR 1.5, 95% CI 1.2-1.9) and need for mechanical ventilation (OR 1.9, 95% CI 1.4-2.5), but was not associated with mortality (OR 1.1, 95% CI 0.8-1.4). Patients with respiratory syncytial virus (RSV) were equally likely to require ICU admission (OR 1.09, 95% CI 0.67-1.78), and more likely to need non-invasive ventilation (OR 3.1; 95% CI 1.8-5.1) compared to patients with influenza. INTERPRETATION: Our results suggest COPD patients requiring hospitalization for respiratory symptoms should routinely receive viral testing at admission, especially for RSV and influenza, to inform prognosis, clinical management, and infection control practices during winter seasons. Patients with COPD will be an important target population for newly developed RSV therapeutics. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01517191.
BACKGROUND: Seasonal respiratory viral infections are associated with exacerbations and morbidity among patients with COPD. The real-world clinical outcomes associated with seasonal viral infections are less well established among hospitalized patients. RESEARCH QUESTION: To estimate the association between seasonal respiratory viral infections, 30-day mortality, and intensive care unit (ICU) admission among hospitalized COPD patients. STUDY DESIGN AND METHODS: We conducted an analysis of a national prospective multicenter cohort of COPD patients hospitalized with acute respiratory illness during winter seasons (2011-2015) in Canada. Nasopharyngeal swabs were performed on all patients at the onset of hospital admission for diagnosis of viral infection. Primary outcomes were 30-day mortality and ICU admissions. Secondary outcomes included invasive/non-invasive ventilation use. RESULTS: Among 3931 hospitalized patients with COPD, 28.5% (1122/3931) were diagnosed with seasonal respiratory viral infection. Viral infection was associated with increased admission to ICU (OR 1.5, 95% CI 1.2-1.9) and need for mechanical ventilation (OR 1.9, 95% CI 1.4-2.5), but was not associated with mortality (OR 1.1, 95% CI 0.8-1.4). Patients with respiratory syncytial virus (RSV) were equally likely to require ICU admission (OR 1.09, 95% CI 0.67-1.78), and more likely to need non-invasive ventilation (OR 3.1; 95% CI 1.8-5.1) compared to patients with influenza. INTERPRETATION: Our results suggest COPD patients requiring hospitalization for respiratory symptoms should routinely receive viral testing at admission, especially for RSV and influenza, to inform prognosis, clinical management, and infection control practices during winter seasons. Patients with COPD will be an important target population for newly developed RSV therapeutics. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01517191.
Authors: Anastasia F Hutchinson; Anil K Ghimire; Michelle A Thompson; Jim F Black; Caroline A Brand; Adrian J Lowe; David M Smallwood; Ross Vlahos; Steven Bozinovski; Graham V Brown; Gary P Anderson; Louis B Irving Journal: Respir Med Date: 2007-09-05 Impact factor: 3.415
Authors: Parvaiz A Koul; Umar H Khan; Romana Asad; Rubaya Yousuf; Shobha Broor; Renu B Lal; Fatimah S Dawood Journal: Influenza Other Respir Viruses Date: 2015-01 Impact factor: 4.380
Authors: P Loubet; N Lenzi; M Valette; V Foulongne; A Krivine; N Houhou; G Lagathu; S Rogez; S Alain; X Duval; F Galtier; D Postil; P Tattevin; P Vanhems; F Carrat; B Lina; O Launay Journal: Clin Microbiol Infect Date: 2016-11-27 Impact factor: 8.067
Authors: Tristan W Clark; Marie-jo Medina; Sally Batham; Martin D Curran; Surendra Parmar; Karl G Nicholson Journal: J Infect Date: 2014-08-06 Impact factor: 6.072
Authors: Sunita Mulpuru; Melissa K Andrew; Lingyun Ye; Todd Hatchette; Jason LeBlanc; May El-Sherif; Donna MacKinnon-Cameron; Shawn D Aaron; Gonzalo G Alvarez; Alan J Forster; Ardith Ambrose; Shelly A McNeil Journal: Influenza Other Respir Viruses Date: 2022-09-07 Impact factor: 5.606